Nexel

Provider of induced pluripotent stem cell (iPSC)-derived cells and organoids

placeSeoul, Seoul, South Korea calendar_todayFounded 2012 groups22 employees language nexel.co.kr

Registered entities

Innovation

29 patent families (6 granted) — focus: Chemistry & metallurgy, Human necessities, Physics & computing; filing pace steady. Cited 327 times.

YearFilings
20173
20183
20193
202011
20214
20225
20234
20247
20257
20262

Social engagement

Social engagement: 789 social following, 6 posts in the last 12 months — below the industry typical range.

Investor mix

13 investors on record; lead investors include NH Investment & Securities, KBD Capital, Youcai Investment, eBEST INVESTMENT & SECURITIES.

Investor typeCountShare
Venture capital538%
Private equity215%
Accelerator & incubator18%
Bank & private debt18%
Other / undisclosed431%

Recent activity

25 Jun 2026
Milestone
regulatory
27 May 2026
Event
49th Workshop of the Korean Society of Nonclinical Study (KSNS) 2026
Coming soon